Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Kissei Licenses Novel Antidiabetic Agent to GSK
November 4, 2002
- NEW PRODUCTS
November 4, 2002
- Kowa Developing Anti-inflammatory Drugs with Pharmacopoeia of the US
November 4, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
November 4, 2002
- Expecting Synergism in Collaboration with Ranbaxy: Mr Yamaguchi of Nippon Chemiphar
November 4, 2002
- Law on New Drug Organization to Be Presented to Diet
November 4, 2002
- Benesis to Concentrate on Stable Supply of Safe Blood Products
November 4, 2002
- Insurer Regrouping to Make Medical Fees Vary from One Prefecture to Another: Korosho Official
November 4, 2002
- FJPWA Withholds Conclusion on Cooperation in Preliminary Drug Price Survey
November 4, 2002
- EU Presents Proposals for Regulatory Reform in Japan
November 4, 2002
- Price Settlement Rate 53.5% at the End of September: VITAL-NET
November 4, 2002
- REGULATORY NEWS IN BRIEF
November 4, 2002
- Bio Drugs to Account for 30% of All Drugs in 2010: Mr Nagayama at Medical Forum
November 4, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 4, 2002
- WEBSITE NEWS
October 28, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
October 28, 2002
- BUSINESS NEWS IN BRIEF
October 28, 2002
- Matsumotokiyoshi Ties Up with Koyo Yakuhin
October 28, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
October 28, 2002
- Interim Report Drafted on Promotion of OTC Drugs
October 28, 2002
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…